Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Upbeat On China Prospects For New Products

Executive Summary

China continues to be the brightest star in AstraZeneca's emerging markets firmament amid some "softness" in other countries, and the UK group sees attractive prospects in the country for some of its innovative branded products.

Advertisement

Related Content

AstraZeneca's Iressa May Pave Way For EGFR Inhibitors In Adjuvant Lung Cancer
Multinationals, Patients Benefit From New Approvals As China Speeds Reviews
What’s Separating The Growers And No-Growers In China?
Japan Delays Keytruda Pricing Amid PD-1 Cost Concerns
Deep China Price Cuts Reveal Complex Considerations

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097682

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel